Conference abstract · 14 Sep 2015
Conference abstractPublished 14 Sep 2015
Glycopeptides revisited
Theravance Biopharma, USA
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Vancomycin was isolated from soil from the jungles of Borneo in 1953 by scientists at Eli Lily & Co. It is a naturally occurring antibiotic produced by the soil bacterium Amycolatopsis orientalis (formerly Nocardia orientalis). It was approved in 1958 by the US FDA to treat penicillin resistant staphylococci. Vancomycin has subsequently become a primary treatment for infections due to MRSA, however it is steadily losing potency due to increasing minimum inhibitory concentrations for many strains of MRSA. Since the discovery of vancomycin, several other glycopeptide, lipodepsipeptide, and lipoglycopeptide antibiotics, all members of this class, have been discovered or synthesized including bleomycin (1966), teicoplanin (1975), ramoplanin (1984), dalbavancin (1996), oritavancin (1996), and telavancin (2000). Some of the newer semisynthetic members of this class have multiple mechanisms of action and greater potency against a wider spectrum of Gram-positive pathogens, including those with reduced susceptibility to vancomycin. This presentation will describe the various members of this class and compare their attributes and clinical use. Emphasis will be placed on the declining utility of vancomycin and the advantages of the newer lipoglycopeptides.
Ask about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Commentary · 13 Jun 2023
Presentation of the Potential of Glycopeptides: A Unique Class of Antibiotics in the Fight against Antibiotic Resistance
Short communication · 28 Jul 2022
C-disaccharide glycopeptides as potential anti-cancer vaccines
Research article · 27 Jun 2022
Large Scale Screening and Quantitative Analysis of Site-Specific N-Glycopeptides from Human Serum in Early Alzheimerandrsquo;s Disease Using LC-HCD-PRM-MS
Short communication · 28 May 2022
Amide derivatives of glycopeptide antibiotics to overcome antibiotics resistance
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- BylineArticles whose byline prints “Jon B Bruss”
